Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Difelikefalin in Advanced CKD with Pruritus
NCT05342623Phase 3Terminated
- Sponsor
- Cara Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pruritus comparing Difelikefalin with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving at least a 4-point improvement from baseline in WI-NRS score at Week 12. Started May 2022; status: terminated.
02
Drugs
difelikefalin
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT05342623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342623.